Help
RSS
API
Feed
Maltego
Contact
Domain > www.carricktherapeutics.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2023-06-06
54.204.13.102
(
ClassC
)
2023-12-16
54.225.202.48
(
ClassC
)
2025-08-18
35.171.156.239
(
ClassC
)
2026-02-18
54.183.187.40
(
ClassC
)
Port 443
HTTP/1.1 200 OKDate: Wed, 18 Feb 2026 02:03:58 GMTServer: ApacheX-Frame-Options: SAMEORIGINStrict-Transport-Security: max-age31536000;X-XSS-Protection: 1; modeblockX-Content-Type-Options: nosniffFeature-Policy: microphone none; camera none; geolocation none; screen-wake-lock none;Referrer-Policy: strict-origin-when-cross-originContent-Security-Policy: default-src *.gstatic.com ir.stockpr.com www.carricktherapeutics.com d1io3yog0oux5.cloudfront.net *.equisolve-dev.com *.equisolve.net; script-src *.quotemedia.com *.google.com *.google-analytics.com *.gstatic.com browser-update.org *.hcaptcha.com hcaptcha.com dev-ir.stockpr.com www.youtube.com player.vimeo.com *.googletagmanager.com ir.stockpr.com www.carricktherapeutics.com d1io3yog0oux5.cloudfront.net *.equisolve-dev.com *.equisolve.net unsafe-inline; connect-src *.quotemedia.com *.google.com *.google-analytics.com *.gstatic.com browser-update.org *.hcaptcha.com hcaptcha.com dev-ir.stockpr.com www.youtube.com player.vimeo.com *.googletagmanager.com ir.stockpr.com www.carricktherapeutics.com d1io3yog0oux5.cloudfront.net *.equisolve-dev.com *.equisolve.net unsafe-inline; style-src fonts.googleapis.com *.gstatic.com *.hcaptcha.com hcaptcha.com dev-ir.stockpr.com ir.stockpr.com www.carricktherapeutics.com d1io3yog0oux5.cloudfront.net *.equisolve-dev.com *.equisolve.net unsafe-inline; font-src cdnjs.cloudflare.com/ajax/libs/font-awesome/ fonts.googleapis.com *.gstatic.com ir.stockpr.com www.carricktherapeutics.com d1io3yog0oux5.cloudfront.net *.equisolve-dev.com *.equisolve.net; img-src i.ytimg.com *.globenewswire.com mma.prnewswire.com c212.net ir.stockpr.com www.carricktherapeutics.com d1io3yog0oux5.cloudfront.net *.equisolve-dev.com *.equisolve.net; frame-src *.google.com youtube.com www.youtube.com youtube-nocookie.com www.youtube-nocookie.com vimeo.com player.vimeo.com *.hcaptcha.com hcaptcha.com ir.stockpr.com www.carricktherapeutics.com d1io3yog0oux5.cloudfront.net *.equisolve-dev.com *.equisolve.net; object-src *.gstatic.com ir.stockpr.com www.carricktherapeutics.com d1io3yog0oux5.cloudfront.net *.equisolve-dev.com *.equisolve.net;Vary: Accept-EncodingTransfer-Encoding: chunkedContent-Type: text/html; charsetUTF-8 !DOCTYPE html>html langen> head> meta http-equivx-ua-compatible contentieedge> meta charsetutf-8> link relalternate typeapplication/rss+xml titleCarrick Therapeutics, Inc. - Recent News hrefhttps://www.carricktherapeutics.com/news-media/press-releases/rss /> title>Carrick Therapeutics, Inc./title> link relcanonical hrefhttps://www.carricktherapeutics.com>meta propertyog:url contenthttps://www.carricktherapeutics.com>meta propertyog:site_name contentCarrick Therapeutics, Inc.>meta propertyog:title contentCarrick Therapeutics, Inc.>meta propertyog:type contentwebsite>meta propertyog:image contenthttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/db/2921/26523/social_image_resized.jpg>meta nametwitter:card contentsummary_large_image>script typeapplication/ld+json> {@context:http:\/\/schema.org,@type:Corporation,name:Carrick Therapeutics, Inc.,address:{@type:PostalAddress,streetAddress: ,addressLocality:,postalCode:,addressCountry:},legalName:Carrick Therapeutics, Inc.,description:null,tickerSymbol:,url:https:\/\/www.carricktherapeutics.com,logo:https:\/\/d1io3yog0oux5.cloudfront.net\/_d4fcdc3f1eef88e32cfe969a2cfa8e3c\/carricktherapeutics\/logo.png,image:https:\/\/d1io3yog0oux5.cloudfront.net\/_d4fcdc3f1eef88e32cfe969a2cfa8e3c\/carricktherapeutics\/db\/2921\/26523\/social_image_resized.jpg,sameAs:}/script> meta nameviewport contentinitial-scale1.0, widthdevice-width> link relpreconnect hrefhttps://d1io3yog0oux5.cloudfront.net> link relpreconnect hrefhttps://qmod.quotemedia.com> link relstylesheet hrefhttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/files/theme/css/style.css> link relshortcut icon hrefhttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/files/theme/images/favicons/favicon.ico> link relapple-touch-icon sizes180x180 hrefhttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/files/theme/images/favicons/apple-touch-icon.png> link relicon typeimage/png hrefhttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/files/theme/images/favicons/favicon-32x32.png sizes32x32> link relicon typeimage/png hrefhttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/files/theme/images/favicons/favicon-16x16.png sizes16x16> link relmanifest hrefhttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/files/theme/images/favicons/manifest.json> link relmask-icon hrefhttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/files/theme/images/favicons/safari-pinned-tab.svg> meta nametheme-color content#ffffff> !-- Google GA4 code (gtag.js) --> script typetext/plain idgoogle-analytics data-typeapplication/javascript data-namegoogle-analytics data-srchttps://www.googletagmanager.com/gtag/js?idG-4MYY1Q9FJZ async >/script>script typetext/plaindata-typeapplication/javascriptdata-namegoogle-analytics> window.dataLayer window.dataLayer || ; function gtag(){dataLayer.push(arguments);} gtag(js, new Date()); gtag(config, G-4MYY1Q9FJZ); /script>!-- END Google GA4 code (gtag.js) --> /head>body class1 page-type-home home has-zero-nav> div classgeneral-wrapper> nav idheader classaffixed aria-labelMain> div idskipLinks> a href#mainContent>Skip to main content/a> a href#footer>Skip to footer/a> /div> div classzero-nav d-none d-lg-block> div classcontainer-fluid zero-nav-container px-0> div classzero-nav-links> a class href/news-media target_self > News & Media /a> a class href/careers target_self > Careers /a> a class href/contact target_self > Contact /a> /div> /div>/div> div classcontainer-fluid> div classd-flex justify-content-between header-container> div classlogo> a href/> img srchttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/files/theme/images/logo-sm.svg width225 height63 altCarrick Therapeutics, Inc.> /a> /div> a rolebutton classmobile-nav-trigger idshowRight aria-labelExpand main navigation aria-controlsmobile-nav> div classmeat>/div> div classmeat>/div> div classmeat>/div> /a> div classcbp-spmenu cbp-spmenu-vertical cbp-spmenu-right main-nav idmobile-nav> ul classmain-menu> li classsr-only p-0 pr-3>a href/>Home/a>/li> li classactive active-landing active active-landing data-submenu-idsubmenu-home> a href/ target_self >Home/a> /li> li classhas-children data-submenu-idsubmenu-about> a href/about target_self >About/a> ul idsubmenu-about> li class> a href/about target_self >Overview/a> /li> li class> a href/about/management-team target_self >Management Team/a> /li> li class> a href/about/board-of-directors-observers target_self >Board of Directors & Observers/a> /li> li class> a href/about/advisors-collaborators target_self >Collaborators & Advisors/a> /li> /ul> /li> li classhas-children data-submenu-idsubmenu-science> a href/science target_self >Science/a> ul idsubmenu-science> li class> a href/science target_self >Overview/a> /li> li class> a href/science/cdk7-biology-schematic target_self >CDK7 Biology Schematic/a> /li> li class> a href/science/cdk1213-biology-schematic target_self >CDK12/13 Biology Schematic/a> /li> li class> a href/science/posters-publications target_self >Posters & Publications/a> /li> /ul> /li> li classhas-children data-submenu-idsubmenu-pipeline> a href/pipeline target_self >Pipeline/a> ul idsubmenu-pipeline> li class> a href/pipeline target_self >Overview/a> /li> li class> a href/pipeline/cdk7-inhibitor target_self >CDK7 Inhibitor/a> /li> li class> a href/pipeline/cdk1213-inhibitor target_self >CDK12/13 Inhibitor/a> /li> /ul> /li> li class last-item data-submenu-idsubmenu-partnering> a href/partnering target_self >Partnering/a> /li> li classd-block d-lg-none> a href/news-media target_self relnoopener> News & Media /a>/li>li classd-block d-lg-none> a href/careers target_self relnoopener> Careers /a>/li>li classd-block d-lg-none> a href/contact target_self relnoopener> Contact /a>/li>/ul> /div> /div> /div>/nav> main idmainContent> div classno-dark page-banner overlay dark home-hero> div classcontainer-fluid pl-0> div classrow justify-content-center> div classcol-md-7 d-flex justify-content-start align-items-start pl-0 > img srchttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/db/2979/26831/image.png alt> /div> div class col-md-10 col-lg-5 > div classtext> h1 classsr-only>Carrick Therapeutics, Inc./h1> h2>Creating a strong foundation for better patient outcomes/h2> p>Carrick Therapeutics is a clinical-stage biopharmaceutical company focused on building the future of oncological therapy to improve patient outcomes. Our extensive experience in developing innovative therapies allows us to deliver a novel best-in-class and first-in-class portfolio./p> a href/about classbtn >About Carrick Therapeutics/a> /div> /div> /div> /div>/div>section classmodule module-full-width row-alt background-gradient banner-full-out > div classcontainer-fluid> div classrow flex-row-reverse> div classbg-image col-lg-6 stylebackground: url(https://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/db/2978/27005/image.png);background-position: 50% 50%;background-repeat: no-repeat;background-size: cover;background-color: #333;>/div> div classcol-lg-6 > div classmodule-content> div classtext> h2>A solid portfolio, backed by good science/h2> p>In order to have the greatest impact on patient lives, we translate in-house and in-licensed assets to target the most aggressive and resistant forms of cancer. Together with our Pharma partners, network of clinicians and scientists across research institutions and hospitals, we are developing ground-breaking cancer therapies./p>div classbtn-row>a href/science classbtn>Explore our science/a> a href/about/advisors-collaborators classbtn> Collaborators & advisors/a>/div> /div> /div> /div> /div> /div>/section>section classmodule module-row-banner background-grey corner-rounded img-top padding-top-200 banner-alt > div classcontainer> div classrow banner-row justify-content-between align-items-center> div classcol-xl-1 image-wrapper> figure classmodule-image> img srchttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/db/2978/27006/image.png alt /> /figure> /div> div classcol-xl-7> div classmodule-content> div classtext-area> div classtext> h2>Building the next generation of advanced cancer therapies/h2> h3 classsubtitle>Novel therapies to address unmet patient needs/h3> p>Our therapies work in combination with existing oncology drugs to target advanced breast, prostate and ovarian cancers, with further potential in pancreatic and Ewings sarcoma./p>div classbtn-row>a href/pipeline/cdk7-inhibitor#clinical-studies classbtn>Samuraciclib clinical studies/a> a href/pipeline classbtn> Explore our pipeline/a>/div> /div> /div> /div> /div> /div> /div>/section>section classmodule module-latest-news-slider stylebackground: linear-gradient(180deg, #fff 25%, transparent), url(https://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/db/2978/27007/background_image.jpg);background-position: 50% 50%;background-repeat: no-repeat;background-size: cover;background-color: #333;position: relative;top: -8px;> div classcontainer> div classrow justify-content-lg-between justify-content-start align-items-center flex-wrap mb-5> div classcol-12 col-lg-auto> h2 classmb-0>Latest News/h2> /div> div classcol-12 col-lg-auto mt-4 mt-lg-0> div classinline-btn mt-0> a hrefhttps://www.carricktherapeutics.com/news-media/press-releases classbtn>View all news/a> /div> /div> /div> div classhidden-sm hidden-xs hidden-md> div classslider-nav>/div> /div> div classrow> div classcol-12> div classnews-slider> div classnews-block> div classcontent data-mhnews-text-box> div classcontent-header> time classdate datetime2025-12-10T13:30:00> Dec 10, 2025 • 1:30 PM EST /time> /div> div classcontent-body> p>a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/27/carrick-therapeutics-announces-positive-results-from-phase>Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer/a>/p> /div> div classcontent-footer> a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/27/carrick-therapeutics-announces-positive-results-from-phase classblock-link>View press release/a> /div> /div> /div> div classnews-block> div classcontent data-mhnews-text-box> div classcontent-header> time classdate datetime2025-05-15T07:00:00> May 15, 2025 • 7:00 AM EDT /time> /div> div classcontent-body> p>a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/26/carrick-therapeutics-announces-new-clinical-data-supporting>Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer/a>/p> /div> div classcontent-footer> a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/26/carrick-therapeutics-announces-new-clinical-data-supporting classblock-link>View press release/a> /div> /div> /div> div classnews-block> div classcontent data-mhnews-text-box> div classcontent-header> time classdate datetime2024-09-23T08:00:00> Sep 23, 2024 • 8:00 AM EDT /time> /div> div classcontent-body> p>a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase>Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)/a>/p> /div> div classcontent-footer> a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase classblock-link>View press release/a> /div> /div> /div> div classnews-block> div classcontent data-mhnews-text-box> div classcontent-header> time classdate datetime2024-06-05T08:00:00> Jun 5, 2024 • 8:00 AM EDT /time> /div> div classcontent-body> p>a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/24/carrick-therapeutics-establishes-new-headquarters-in>Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts/a>/p> /div> div classcontent-footer> a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/24/carrick-therapeutics-establishes-new-headquarters-in classblock-link>View press release/a> /div> /div> /div> div classnews-block> div classcontent data-mhnews-text-box> div classcontent-header> time classdate datetime2024-02-14T08:00:00> Feb 14, 2024 • 8:00 AM EST /time> /div> div classcontent-body> p>a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/23/carrick-therapeutics-announces-first-patient-dosed-in-phase>Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer/a>/p> /div> div classcontent-footer> a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/23/carrick-therapeutics-announces-first-patient-dosed-in-phase classblock-link>View press release/a> /div> /div> /div> div classnews-block> div classcontent data-mhnews-text-box> div classcontent-header> time classdate datetime2023-12-15T08:00:00> Dec 15, 2023 • 8:00 AM EST /time> /div> div classcontent-body> p>a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/22/carrick-therapeutics-announces-first-patient-dosed-in-phase>Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer/a>/p> /div> div classcontent-footer> a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/22/carrick-therapeutics-announces-first-patient-dosed-in-phase classblock-link>View press release/a> /div> /div> /div> div classnews-block> div classcontent data-mhnews-text-box> div classcontent-header> time classdate datetime2023-10-18T09:00:00> Oct 18, 2023 • 9:00 AM EDT /time> /div> div classcontent-body> p>a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/21/carrick-therapeutics-announces-first-patient-dosed-in-phase>Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer/a>/p> /div> div classcontent-footer> a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/21/carrick-therapeutics-announces-first-patient-dosed-in-phase classblock-link>View press release/a> /div> /div> /div> div classnews-block> div classcontent data-mhnews-text-box> div classcontent-header> time classdate datetime2023-09-07T08:00:00> Sep 7, 2023 • 8:00 AM EDT /time> /div> div classcontent-body> p>a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind>Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13/a>/p> /div> div classcontent-footer> a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind classblock-link>View press release/a> /div> /div> /div> div classnews-block> div classcontent data-mhnews-text-box> div classcontent-header> time classdate datetime2023-07-06T09:00:00> Jul 6, 2023 • 9:00 AM EDT /time> /div> div classcontent-body> p>a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/19/carrick-therapeutics-announces-clinical-trial-collaboration>Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination/a>/p> /div> div classcontent-footer> a hrefhttps://www.carricktherapeutics.com/news-media/press-releases/detail/19/carrick-therapeutics-announces-clinical-trial-collaboration classblock-link>View press release/a> /div> /div> /div> /div> /div> /div> /div>/section>section classmodule module-full-width banner-full-out-alt background-grey padding-top-200 > div classcontainer-fluid> div classcontainer> div classrow flex-row-reverse> div classbg-image col-lg-6 stylebackground: url(https://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/db/2978/27009/image.png);background-position: 50% 50%;background-repeat: no-repeat;background-size: cover;background-color: #333;>/div> div classcol-lg-6 > div classmodule-content> div classtext> h2>Email Alerts/h2> p>Stay informed and receive company updates straight to your inbox./p> a href/email-alerts classbtn > Sign up today /a> /div> /div> /div> /div> /div> /div>/section> /main> footer idfooter > div classfooter-main> div classcontainer> div classrow justify-content-between align-items-center> div classcol-md-6> div classcopyright> ©time datetime2026>2026/time> a href/>Carrick Therapeutics, Inc./a> All Rights Reserved. /div> /div> div classcol-md-6> div classfooter-links> a href/privacy-policy>Privacy Policy/a>a href/cookie-policy>Cookie Policy/a>a href/disclaimer>Disclaimer/a>a href/sitemap>Sitemap/a> a hrefhttps://www.linkedin.com/company/carrick-therapeutics/ target_blank relnoopener classsocial-icon> img srchttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/db/2923/27201/icon/linkedin%403x.svg altVisit us on Linkedin height24 width24 /> /a> a idklaroPrefs href# rolebutton>Manage Cookie Preferences/a> /div> /div> /div> /div> /div> /footer>script idcompanyVars typeapplication/json>{ asset_url: https:\/\/d1io3yog0oux5.cloudfront.net\/_d4fcdc3f1eef88e32cfe969a2cfa8e3c\/carricktherapeutics, website_base_url: https:\/\/www.carricktherapeutics.com, ir_base_url: \/investors, hCaptchaSiteKey: 778a5748-d323-4b73-a06c-9625642de8bc, isQmod: false}/script>script srchttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/files/theme/js/aside/klaro-cookie-consent/_js/all.js data-configklaroConfig defer>/script>script srchttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/files/theme/js/_js/all.js>/script> script srchttps://d1io3yog0oux5.cloudfront.net/_d4fcdc3f1eef88e32cfe969a2cfa8e3c/carricktherapeutics/files/theme/js/aside/modules/row-media-news-slider/_js/all.js>/script> script idnewsSlickOptions typeapplication/json> { infinite: false, dots: false, arrows: true, prevArrow: div classprev prev-arrow>/div>, nextArrow: div classnext next-arrow>/div>, appendArrows: .slider-nav, appendDots: .slider-nav, slidesToShow: 3, slidesToScroll: 3, responsive: { breakpoint: 1199, settings: { slidesToShow: 3, variableWidth: false, slidesToScroll: 3 } }, { breakpoint: 991, settings: { slidesToShow: 2, variableWidth: false, slidesToScroll: 1 } }, { breakpoint: 767, settings: { slidesToShow: 1, variableWidth: false, slidesToScroll: 1 } } } /script> /div>!-- //general-wrapper -->/body>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]